An Open Label Clinical Trial to Evaluate the Efficacy and Tolerance of a Retinol and Vitamin C Facial Regimen in Women With Mild-to-Moderate Hyperpigmentation and Photodamaged Facial Skin - JDDonline - Journal
What is a PP Population, or 'Per Protocol' Population in a Clinical Trial? - Quantics Biostatistics
Randomized clinical trial: the effect of probiotic Bacillus coagulans Unique IS2 vs. placebo on the symptoms management of irritable bowel syndrome in adults | Scientific Reports
Untitled
Intention to Treat - YouTube
Intention-to-treat analysis may be more conservative than per protocol analysis in antibiotic non-inferiority trials: a systematic review | BMC Medical Research Methodology | Full Text
Intention-to-treat principle | CMAJ
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial - The Lancet Infectious Diseases
Figure 2, Forest Plot For ACR20 Responses at Week 24 in SUMMACTA and MUSASHI Studies for the Per-Protocol Population - Tocilizumab (Actemra) - NCBI Bookshelf
What is a PP Population, or 'Per Protocol' Population in a Clinical Trial? - Quantics Biostatistics
INTENTION TO TREAT AND PER PROTOCOL ANALYSIS IN CLINICAL TRIALS
Intention-to-Treat (ITT) - ppt video online download
Trial profile. Population: ITT = intention-to-treat, PP = per protocol. | Download Scientific Diagram
Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?
Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites | PLOS Medicine
Table 1 from Per-Protocol Analyses of Pragmatic Trials. | Semantic Scholar
Intention-To-Treat (ITT) vs. Per Protocol (PP) analysis in clinical trials
Journal of Stroke
Trial population profiles. ITT: intention-to-treat; PP: per protocol. | Download Scientific Diagram
Results - Clinical Review Report: Ocrelizumab (Ocrevus) - NCBI Bookshelf
Untitled
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | NEJM
Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial
Screening: the information individuals need to support their decision: per protocol analysis is better than intention-to-treat analysis at quantifying potential benefits and harms of screening | BMC Medical Ethics | Full Text
